Eris Lifesciences Share Price
Eris Lifesciences Share Price Today
As of 6 Jul 2026, Eris Lifesciences share price is ₹1,431.10. The stock opened at ₹1,455.90, compared to its previous close of ₹1,448.70. During today's trading session, Eris Lifesciences share price moved in the range of ₹1,424.60 to ₹1,465.00, with an average price of ₹1,444.80 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,200.00 and a high of ₹1,885.00. On the performance front, Eris Lifesciences share price has declined by 6.68% over the last six months and is down 16.73% on a year-on-year basis.
Eris Lifesciences Returns Calculator
Eris Lifesciences Shareholder Returns
Eris Lifesciences Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Eris Lifesciences Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹2,893.64 | ₹2,009.15 | ₹1,685.15 | ₹1,347.04 |
| Other Income | ₹18.36 | ₹23.82 | ₹11.15 | ₹26.09 |
| Total Revenue | ₹2,912.00 | ₹2,032.97 | ₹1,696.30 | ₹1,373.14 |
| Total Expenses | ₹2,423.19 | ₹1,601.63 | ₹1,291.66 | ₹930.94 |
| Profit Before Tax | ₹488.87 | ₹431.34 | ₹404.64 | ₹442.20 |
| Tax | ₹114.20 | ₹34.22 | ₹30.48 | ₹36.41 |
| Profit After Tax | ₹374.67 | ₹397.12 | ₹374.16 | ₹405.79 |
| EPS - Basic | ₹25.85 | ₹28.82 | ₹28.10 | ₹29.89 |
| EPS - Diluted | ₹25.81 | ₹28.79 | ₹28.07 | ₹29.88 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹488.87 | ₹431.34 | ₹404.64 | ₹442.20 |
| Income before WC changes | ₹1,036.92 | ₹685.50 | ₹544.48 | ₹491.45 |
| Change in Assets | ₹15.99 | -₹90.25 | -₹188.85 | -₹58.61 |
| Change in Liabilities | ₹109.98 | -₹8.49 | ₹13.32 | ₹28.71 |
| Change in WC | ₹125.97 | -₹98.74 | -₹175.54 | -₹29.90 |
| Cash flow from Operations | ₹1,065.01 | ₹486.01 | ₹291.74 | ₹378.26 |
| Cash flow from Investing | -₹79.97 | -₹1,854.52 | -₹982.10 | -₹319.61 |
| Cash flow from Financing | -₹881.32 | ₹1,379.78 | ₹688.03 | -₹44.70 |
| Total Cash Flow | ₹103.72 | ₹11.27 | -₹2.34 | ₹13.96 |
| Cash (Start of the year) | ₹94.25 | ₹56.02 | ₹50.87 | ₹36.92 |
| Cash (End of the year) | ₹199.74 | ₹94.15 | ₹56.02 | ₹50.87 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹5,810.18 | ₹4,738.42 | ₹2,902.61 | ₹1,644.81 |
| Current Assets | ₹1,222.99 | ₹2,302.04 | ₹764.72 | ₹627.33 |
| Total Assets | ₹7,033.17 | ₹7,040.46 | ₹3,667.33 | ₹2,272.14 |
| Current Liabilities | ₹1,381.39 | ₹2,532.07 | ₹443.23 | ₹199.65 |
| Net Current Asset | -₹158.40 | -₹230.03 | ₹321.49 | ₹427.68 |
| Non-Current Liabilities | ₹2,380.02 | ₹1,286.30 | ₹1,003.42 | ₹164.29 |
| Equity Capital | ₹3,271.76 | ₹3,222.09 | ₹2,220.68 | ₹1,908.20 |
| Total Equity & Liabilities | ₹7,033.17 | ₹7,040.46 | ₹3,667.33 | ₹2,272.14 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,697.75 | ₹1,486.71 | ₹1,330.73 | ₹1,215.73 |
| Other Income | ₹35.51 | ₹34.83 | ₹17.26 | ₹28.99 |
| Total Revenue | ₹1,733.26 | ₹1,521.54 | ₹1,347.99 | ₹1,244.72 |
| Total Expenses | ₹1,613.21 | ₹1,192.70 | ₹911.08 | ₹786.18 |
| Profit Before Tax | ₹120.05 | ₹328.84 | ₹436.91 | ₹458.54 |
| Tax | ₹42.66 | ₹29.12 | ₹38.90 | ₹41.35 |
| Profit After Tax | ₹77.39 | ₹299.72 | ₹398.01 | ₹417.19 |
| EPS - Basic | ₹5.69 | ₹22.04 | ₹29.27 | ₹30.70 |
| EPS - Diluted | ₹5.68 | ₹22.01 | ₹29.23 | ₹30.70 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹120.05 | ₹328.83 | ₹436.91 | ₹458.54 |
| Income before WC changes | ₹513.61 | ₹472.95 | ₹510.61 | ₹489.57 |
| Change in Assets | ₹117.87 | -₹102.33 | -₹122.00 | -₹57.75 |
| Change in Liabilities | ₹83.82 | ₹39.15 | ₹11.50 | ₹20.49 |
| Change in WC | ₹201.69 | -₹63.18 | -₹110.50 | -₹37.26 |
| Cash flow from Operations | ₹701.86 | ₹336.29 | ₹322.33 | ₹369.41 |
| Cash flow from Investing | -₹358.99 | -₹2,491.89 | -₹513.30 | -₹267.64 |
| Cash flow from Financing | -₹310.46 | ₹2,160.05 | ₹193.75 | -₹88.42 |
| Total Cash Flow | ₹32.41 | ₹4.45 | ₹2.78 | ₹13.36 |
| Cash (Start of the year) | ₹51.93 | ₹47.48 | ₹44.70 | ₹31.35 |
| Cash (End of the year) | ₹84.34 | ₹51.93 | ₹47.48 | ₹44.70 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹4,594.89 | ₹3,473.03 | ₹2,231.58 | ₹1,570.41 |
| Current Assets | ₹627.54 | ₹1,876.54 | ₹552.08 | ₹580.01 |
| Total Assets | ₹5,222.43 | ₹5,349.57 | ₹2,783.66 | ₹2,150.42 |
| Current Liabilities | ₹993.94 | ₹2,261.79 | ₹283.77 | ₹166.24 |
| Net Current Asset | -₹366.40 | -₹385.25 | ₹268.30 | ₹413.77 |
| Non-Current Liabilities | ₹1,713.59 | ₹563.76 | ₹278.00 | ₹65.62 |
| Equity Capital | ₹2,514.90 | ₹2,524.02 | ₹2,221.88 | ₹1,918.56 |
| Total Equity & Liabilities | ₹5,222.43 | ₹5,349.57 | ₹2,783.66 | ₹2,150.42 |
About Eris Lifesciences
Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.
Eris Lifesciences Financial Highlights
- Revenue: Eris Lifesciences reported revenue of ₹3,137.17 crore in FY26 vs ₹2,912.00 crore in FY25. It showed an increase of 7.73% on a yearly basis.
- Operating Profit: Eris Lifesciences reported an operating profit of ₹638.54 crore in FY26 vs ₹488.87 crore in FY25. It showed an increase of 30.62% on a year-on-year basis.
- Net Profit: Eris Lifesciences reported a net profit of ₹647.51 crore in FY26 vs ₹374.67 crore in FY25. It showed an increase of 72.82% on a yearly basis.
Eris Lifesciences Quarterly Result Highlights
- Eris Lifesciences reported revenue of ₹758.79 crore in Mar 2026, compared with ₹807.47 crore in Dec 2025, representing a decrease of 6.03% on a quarter-on-quarter (QoQ) basis.
- Eris Lifesciences reported an operating profit of ₹159.41 crore in Mar 2026, compared with ₹145.35 crore in Dec 2025, representing an increase of 9.67% on a quarter-on-quarter (QoQ) basis.
- Eris Lifesciences reported a profit of ₹279.10 crore in Mar 2026, compared with ₹108.83 crore in Dec 2025, reflecting an increase of 156.46% on a QoQ basis.
- The earnings per share (EPS) of Eris Lifesciences stood at ₹25.85 during Mar 2026.
Similar Stocks
FAQs on Eris Lifesciences Share Price
What is Eris Lifesciences share price today?
Eris Lifesciences share price is ₹1,431.10 as on 03 Jul, 2026, 15:40 IST.
How has the Eris Lifesciences share price performed in the past?
In the last 1 year, Eris Lifesciences delivered a return of -16.73%. The Eris Lifesciences share price hit a high of ₹1,885.00 and low of ₹1,200.00.
How much is the Mutual Fund shareholding in Eris Lifesciences shares?
The Mutual Fund Shareholding in Eris Lifesciences was 18.22% at the end of Mar 2026.
What is the the 52-week high and low of Eris Lifesciences shares ?
The 52-week high and low of Eris Lifesciences share is ₹1,885.00 and ₹1,200.00 as of 03 Jul, 2026.
What is the market cap of Eris Lifesciences?
The market capitalisation of Eris Lifesciences is ₹20,055.80 Crores as on 03 Jul, 2026.
What are the stock symbols of Eris Lifesciences?
The stock symbol of Eris Lifesciences is ERIS on the NSE, 540596 on the BSE, and the ISIN is INE406M01024.
What was yesterday's closing price of Eris Lifesciences shares ?
Eris Lifesciences shares closed yesterday at ₹1,448.70 on NSE & ₹1,447.25 on BSE
How to buy Eris Lifesciences shares?
To buy Eris Lifesciences shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Eris Lifesciences shares on Holidays?
No, shares of Eris Lifesciences or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Eris Lifesciences shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Eris Lifesciences?
The PE and PB ratio of Eris Lifesciences is 30.97 and 5.14 respectively, as on 03 Jul, 2026, 15:40 IST.